logo-loader
viewMetallica Minerals Limited

Metallica Minerals’ study supports development of bauxite project

Metallica Minerals (ASX:MLM) has successfully completed an independent pre-feasibility study (PFS) supporting the development of the Urquhart Bauxite project in Queensland’s Cape York.

qsld__757_585afff09ec59.jpg
Metallica Minerals’ study supports development of bauxite project

The company’s shares were last trading at $0.053, up 15.22% intraday.

Metallica’s PFS estimates pre-tax project net present value of $78.4 million on sales of 6.5 million tonnes of bauxite (proved and probable reserves).

The PFS base case points to a potential revenue stream nearing $300 million across 5.5 years of production with a payback period of just five months.

The project is expected to generate a strong total operating margin of around $12 per tonne.

Metallica has a 50% share of the Urquhart Bauxite joint venture and plans to develop it via a contractor model so as to minimise mine start-up capital and maximise returns.

The joint venture is in the process of negotiating a mining and haulage contract with an appropriately qualified contractor.

The high-margin bauxite in Area A of the project is slated for first production in Q2 2017.

Metallica is targeting a production rate of 1.5 million tonnes per annum by 2019.

The company had a cash balance of circa $1.5 million as at 30 September 2016.

Quick facts: Metallica Minerals Limited

Price: 0.013 AUD

ASX:MLM
Market: ASX
Market Cap: $4.21 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Redx Pharma's chief scientific officer talks grant funding for its fibrosis...

Redx Pharma PLC's (LON:REDX) chief scientific officer Dr Richard Armer speaks to Proactive London's Andrew Scott after announcing they'd won grant funding for their latest project. They're collaborating with the Medicines Discovery Catapult, a government body that helps accelerate the...

19 minutes ago

2 min read